This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Neogen Gains on Strong Genomic Arm Amid Stiff Competition
by Zacks Equity Research
Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.
Why Is Neogen (NEOG) Up 9.4% Since Last Earnings Report?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Neogen's Canadian Lab Buyout to Boost Genomics Business
by Zacks Equity Research
Neogen (NEOG) continues to adopt initiatives to boost the genomics business.
Neogen (NEOG) Q2 Earnings Beat Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 3.33% and -1.71%, respectively, for the quarter ended November 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Neogen (NEOG) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Sweta Killa
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Neogen (NEOG) Down 17.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen (NEOG) Earnings Beat, Revenues Lag Estimates in Q1
by Zacks Equity Research
Accretive integrations and an expanding international footprint drive Neogen's (NEOG) earnings in Q1.
Neogen (NEOG) Q1 Earnings Beat Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 3.57% and -3.71%, respectively, for the quarter ended August 2018. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Q1 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neogen's Livestock Genetic Buyout Expands Animal Safety Suite
by Zacks Equity Research
The acquisition of Livestock Genetic will position Neogen (NEOG) as a leading agrigenomics company worldwide.
Neogen's (NEOG) Listeria Right Now Gets Approval from AOAC
by Zacks Equity Research
Neogen's (NEOG) Listeria Right Now likely to prove beneficial in preventing food-borne diseases in the United States.
Neogen (NEOG) Up 1.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen (NEOG) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Neogen (NEOG) sticks to its four-pronged growth strategy for steady progress. Also, the company's accretive buyouts and its broader international base are a boon.
Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for DWAS
Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DWAS
Neogen (NEOG) Q3 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Neogen (NEOG) witnesses year-over-year revenue increase in both the segments in Q3.
Haemonetics (HAE) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Haemonetics (HAE) gains from promising financial results in the third quarter of fiscal 2018.
Masimo's (MASI) Eve Gets CE Mark, Bolsters CCHD Diagnosis
by Zacks Equity Research
Masimo's (MASI) newborn screening application, Eve, will make CCHD diagnosis simple and cost effective.
5 Top Earnings Growth Stocks to Buy in February
by Tirthankar Chakraborty
We have shortlisted 5 top-rated stocks that have striking earnings growth and positive estimate revisions.
CVS Health Grows in PBM With Rheumatoid Arthritis Program
by Zacks Equity Research
The new Transform Rheumatoid Arthritis Care program to help CVS Health (CVS) provide a personalized whole-patient support through specialty pharmacy and embedded AccordantCare nurses.
Positive Market Trends Aid Cardiovascular Systems Amid Woes
by Zacks Equity Research
Cardiovascular Systems (CSII) firmly stands to gain from several favorable trends existing in the PAD and CAD market spaces.
BD's CE Mark and Check-Point's Screening Test to Fight CPO
by Zacks Equity Research
BD (BDX)-Check-Points' advanced bacterial screening assay will help lower mortality rates caused by AMR.